These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1362616)

  • 21. Noninvasive in vivo detection of a fluorinated neuroleptic in the human brain by 19F nuclear magnetic resonance spectroscopy.
    Durst P; Schuff N; Crocq MA; Mokrani MC; Macher JP
    Psychiatry Res; 1990 Dec; 35(2):107-14. PubMed ID: 2100803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measurement of human brain dexfenfluramine concentration by 19F magnetic resonance spectroscopy.
    Christensen JD; Yurgelun-Todd DA; Babb SM; Gruber SA; Cohen BM; Renshaw PF
    Brain Res; 1999 Jul; 834(1-2):1-5. PubMed ID: 10407087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of anti-psychotic drugs.
    Mackay AV
    Br J Clin Pharmacol; 1981 Mar; 11(3):225-36. PubMed ID: 6111332
    [No Abstract]   [Full Text] [Related]  

  • 24. Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics.
    Presant CA; Wolf W; Albright MJ; Servis KL; Ring R; Atkinson D; Ong RL; Wiseman C; King M; Blayney D
    J Clin Oncol; 1990 Nov; 8(11):1868-73. PubMed ID: 2230874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response of thyrotropin to thyrotropin-releasing hormone as predictor of treatment outcome. Prediction of recovery and relapse in treatment with antidepressants and neuroleptics.
    Langer G; Koinig G; Hatzinger R; Schönbeck G; Resch F; Aschauer H; Keshavan MS; Sieghart W
    Arch Gen Psychiatry; 1986 Sep; 43(9):861-8. PubMed ID: 2875702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Managing psychotic symptoms when the diagnosis is unclear.
    Ninan PT; Shelton S
    Hosp Community Psychiatry; 1993 Feb; 44(2):107-8. PubMed ID: 8432491
    [No Abstract]   [Full Text] [Related]  

  • 27. Brain volume changes in schizophrenia: how do they arise? What do they mean?
    Lewis DA
    Psychol Med; 2009 Nov; 39(11):1779-80. PubMed ID: 19379533
    [No Abstract]   [Full Text] [Related]  

  • 28. Schizoaffective disorder: a form of schizophrenia or affective disorder?
    Evans JD; Heaton RK; Paulsen JS; McAdams LA; Heaton SC; Jeste DV
    J Clin Psychiatry; 1999 Dec; 60(12):874-82. PubMed ID: 10665641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Depression in first-episode schizophrenia.
    Koreen AR; Siris SG; Chakos M; Alvir J; Mayerhoff D; Lieberman J
    Am J Psychiatry; 1993 Nov; 150(11):1643-8. PubMed ID: 8105706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome study of first-episode psychosis. I: Relapse rates after 1 year.
    Rabiner CJ; Wegner JT; Kane JM
    Am J Psychiatry; 1986 Sep; 143(9):1155-8. PubMed ID: 2875663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of antipsychotics on brain structure: what have we learnt from structural imaging of schizophrenia?
    Borgwardt SJ; Smieskova R; Fusar-Poli P; Bendfeldt K; Riecher-Rössler A
    Psychol Med; 2009 Nov; 39(11):1781-2. PubMed ID: 19476691
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-acting injectable risperidone in treatment refractory patients: a 14-week open-label pilot study.
    Procyshyn RM; Barr AM; Flynn S; Schenk C; Ganesan S; Honer WG
    Schizophr Res; 2010 Nov; 123(2-3):273-5. PubMed ID: 20688481
    [No Abstract]   [Full Text] [Related]  

  • 33. Negative priming (cognitive inhibition) in psychiatric patients: effect of neuroleptics.
    David AS
    J Nerv Ment Dis; 1995 May; 183(5):337-9. PubMed ID: 7745390
    [No Abstract]   [Full Text] [Related]  

  • 34. Predicting medication-free treatment response in acute psychosis: cross-validation from the Finnish Need-Adapted Project.
    Bola JR; Lehtinen K; Aaltonen J; Räkköläinen V; Syvälahti E; Lehtinen V
    J Nerv Ment Dis; 2006 Oct; 194(10):732-9. PubMed ID: 17041284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A treatment-relevant classification of psychotic disorders.
    McGorry P
    Aust N Z J Psychiatry; 1995 Dec; 29(4):555-8. PubMed ID: 8825814
    [No Abstract]   [Full Text] [Related]  

  • 36. Concordance of patient and clinical ratings of symptom severity and change of psychotic illness.
    Rabinowitz J; Levine SZ; Medori R; Oosthuizen P; Koen L; Emsley R
    Schizophr Res; 2008 Mar; 100(1-3):359-60. PubMed ID: 18077138
    [No Abstract]   [Full Text] [Related]  

  • 37. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia.
    Minzenberg MJ; Poole JH; Benton C; Vinogradov S
    Am J Psychiatry; 2004 Jan; 161(1):116-24. PubMed ID: 14702259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacologic treatment of the psychotic symptoms in schizophrenia].
    Goldchluk A
    Vertex; 2002; 13 Suppl 1():4-11. PubMed ID: 12122421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ["Sluggish schizophrenia" (concerning the article by A.B. Smulevich and P.V. Mikhalev (S.S. Korsakov zhurnal nevropatologii i psikhiatrii, No. 12, l987, pp. 186-187].
    Aliev N
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1992; 92(2):132. PubMed ID: 1355941
    [No Abstract]   [Full Text] [Related]  

  • 40. The Northwick Park 'Functional' Psychosis Study: diagnosis and outcome.
    Johnstone EC; Frith CD; Crow TJ; Owens DG; Done DJ; Baldwin EJ; Charlette A
    Psychol Med; 1992 May; 22(2):331-46. PubMed ID: 1352049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.